Date: 2016-02-10
Type of information: Nomination
Compound:
Company: European Generic Medicines Association (EGA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 10, 2016, Sandoz announced that the European Generic Medicines Association (EGA) has elected Carol Lynch, Global Head Biopharmaceuticals & Oncology Injectables, Sandoz as Chair of its European Biosimilars Group (EBG). In this role Lynch, along with fellow EBG members, will support the expansion of patient access to high-quality biosimilar medicines, while ensuring the sustainability of the industry. Lynch believes that the industry’s areas of focus, under her tenure, for the next two years should be increasing stakeholder awareness and understanding through education, strengthening regulatory and scientific concepts and advocating for industrial policies that supports growth of the biosimilars industry.
Carol Lynch leads a 3000+ person organization focused on the development, manufacturing and commercialization of biosimilars and oncology injectables. She is also responsible for Sandoz’s biopharmaceutical contract manufacturing business. Prior to joining Sandoz in 2014, Lynch held several Commercial and Development leadership positions in Novartis Pharmaceuticals both globally and in country organizations, including the United States. She is a member of the Sandoz Executive Committee, and Chair of the European Biosimilars Group.
Financial terms:
Latest news:
